Tomoki Todo

9.7k total citations · 4 hit papers
143 papers, 7.2k citations indexed

About

Tomoki Todo is a scholar working on Molecular Biology, Genetics and Epidemiology. According to data from OpenAlex, Tomoki Todo has authored 143 papers receiving a total of 7.2k indexed citations (citations by other indexed papers that have themselves been cited), including 70 papers in Molecular Biology, 62 papers in Genetics and 54 papers in Epidemiology. Recurrent topics in Tomoki Todo's work include Virus-based gene therapy research (62 papers), Herpesvirus Infections and Treatments (40 papers) and CAR-T cell therapy research (32 papers). Tomoki Todo is often cited by papers focused on Virus-based gene therapy research (62 papers), Herpesvirus Infections and Treatments (40 papers) and CAR-T cell therapy research (32 papers). Tomoki Todo collaborates with scholars based in Japan, United States and Germany. Tomoki Todo's co-authors include Yasushi Ino, Samuel D. Rabkin, Hiroshi Fukuhara, Robert L. Martuza, Minoru Tanaka, Paul A. Johnson, Kohei Miyazono, Frank Feigenbaum, Keiji Miyazawa and Nobuhito Saito and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Journal of Biological Chemistry.

In The Last Decade

Tomoki Todo

141 papers receiving 7.0k citations

Hit Papers

Conditionally replicating herpes simplex virus mutant, G2... 2000 2026 2008 2017 2000 2016 2022 2022 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial
    2000 794 citations Samuel D. Rabkin, Tomoki Todo et al. profile →
  2. Oncolytic virus therapy: A new era of cancer treatment at dawn
    2016 564 citations Hiroshi Fukuhara, Yasushi Ino et al. profile →
  3. Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial
    2022 317 citations Tomoki Todo, Hirotaka Ito et al. Nature Medicine profile →
  4. A phase I/II study of triple-mutated oncolytic herpes virus G47∆ in patients with progressive glioblastoma
    2022 135 citations Tomoki Todo, Yasushi Ino et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tomoki Todo Japan 43 3.4k 3.1k 2.8k 1.8k 973 143 7.2k
James M. Markert United States 48 4.4k 1.3× 3.2k 1.0× 3.5k 1.2× 2.3k 1.3× 1.6k 1.7× 199 8.5k
Samuel D. Rabkin United States 55 7.3k 2.2× 5.4k 1.7× 4.9k 1.7× 3.4k 1.9× 879 0.9× 170 11.1k
Cheryl A. Palmer United States 33 1.5k 0.5× 1.5k 0.5× 1.2k 0.4× 1.1k 0.6× 761 0.8× 105 4.5k
Ulrike Blömer Germany 20 4.6k 1.4× 5.6k 1.8× 929 0.3× 946 0.5× 552 0.6× 34 8.2k
Robert L. Martuza United States 60 6.1k 1.8× 5.0k 1.6× 4.7k 1.7× 5.4k 3.0× 1.8k 1.8× 173 13.4k
David A. Largaespada United States 57 2.6k 0.8× 7.8k 2.5× 1.9k 0.7× 511 0.3× 924 0.9× 213 11.8k
Romain Zufferey Switzerland 22 4.4k 1.3× 5.7k 1.8× 1.2k 0.4× 744 0.4× 324 0.3× 30 8.2k
Ya‐Wen Chiang United States 26 2.6k 0.8× 2.6k 0.8× 1.3k 0.5× 502 0.3× 257 0.3× 42 4.5k
Federico Mingozzi United States 49 6.9k 2.0× 7.1k 2.3× 2.6k 0.9× 994 0.6× 532 0.5× 122 10.3k
Nicholas C. Dracopoli United States 37 1.9k 0.6× 4.2k 1.3× 2.8k 1.0× 385 0.2× 229 0.2× 88 7.6k

Countries citing papers authored by Tomoki Todo

Since Specialization
Citations

This map shows the geographic impact of Tomoki Todo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tomoki Todo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tomoki Todo more than expected).

Fields of papers citing papers by Tomoki Todo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tomoki Todo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tomoki Todo. The network helps show where Tomoki Todo may publish in the future.

Co-authorship network of co-authors of Tomoki Todo

This figure shows the co-authorship network connecting the top 25 collaborators of Tomoki Todo. A scholar is included among the top collaborators of Tomoki Todo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tomoki Todo. Tomoki Todo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Fukuhara, Hiroshi, et al.. (2023). Fusion peptide is superior to co-expressing subunits for arming oncolytic herpes virus with interleukin 12. SHILAP Revista de lepidopterología. 3(1). 40–40. 4 indexed citations
2.
Fukasawa, Kazuya, Akane Suzuki, Tetsuhiro Horie, et al.. (2023). MEK5-ERK5 Axis Promotes Self-renewal and Tumorigenicity of Glioma Stem Cells. Cancer Research Communications. 3(1). 148–159. 8 indexed citations
3.
Todo, Tomoki, Hirotaka Ito, Yasushi Ino, et al.. (2022). Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial. Nature Medicine. 28(8). 1630–1639. 317 indexed citations breakdown →
4.
Tanabe, Ryo, Kohei Miyazono, Tomoki Todo, et al.. (2021). PRRX1 induced by BMP signaling decreases tumorigenesis by epigenetically regulating glioma‐initiating cell properties via DNA methyltransferase 3A. Molecular Oncology. 16(1). 269–288. 6 indexed citations
5.
Nakahara, Hirokazu, Hiroshi Fukuhara, Miwako Iwai, et al.. (2021). Oncolytic herpes virus G47Δ injected into tongue cancer swiftly traffics in lymphatics and suppresses metastasis. Molecular Therapy — Oncolytics. 22. 388–398. 17 indexed citations
6.
Imataki, Osamu, et al.. (2020). Oncolytic herpes simplex virus type 1 (HSV‐1) in combination with lenalidomide for plasma cell neoplasms. British Journal of Haematology. 192(2). 343–353. 17 indexed citations
7.
Heike, Toshio, Naoshi Sugimoto, Osamu Imataki, et al.. (2020). Oncolytic Virus Therapy with HSV-1 for Hematological Malignancies. Molecular Therapy. 29(2). 762–774. 26 indexed citations
8.
Yamada, Tomoharu, Ryosuke Tateishi, Miwako Iwai, Kazuhiko Koike, & Tomoki Todo. (2020). Neoadjuvant Use of Oncolytic Herpes Virus G47Δ Enhances the Antitumor Efficacy of Radiofrequency Ablation. Molecular Therapy — Oncolytics. 18. 535–545. 28 indexed citations
9.
Ino, Yasushi, et al.. (2017). P3.02c-013 Combination Therapy of Oncolytic Herpes Simplex Virus Type 1 with Erlotinib in a Human Lung Cancer Xenograft Model. Journal of Thoracic Oncology. 12(1). S1279–S1279. 1 indexed citations
10.
Koso, Hideto, Paul Sheridan, Satoru Miyano, et al.. (2016). Identification of RNA-Binding Protein LARP4B as a Tumor Suppressor in Glioma. Cancer Research. 76(8). 2254–2264. 43 indexed citations
11.
Ino, Yasushi, et al.. (2016). 412. The Efficacy and Bio-Distribution of Oncolytic HSV-1 (G47Δ) in Mouse Orthotopic Esophageal Cancer Models. Molecular Therapy. 24. S163–S163. 1 indexed citations
12.
Muraguchi, Teruyuki, Shingo Tanaka, Daisuke Yamada, et al.. (2010). NKX2.2 Suppresses Self-Renewal of Glioma-Initiating Cells. Cancer Research. 71(3). 1135–1145. 21 indexed citations
13.
Koga, Tomoyuki, Akio Morita, Keisuke Maruyama, et al.. (2009). Long-term control of disseminated pleomorphic xanthoastrocytoma with anaplastic features by means of stereotactic irradiation. Neuro-Oncology. 11(4). 446–451. 43 indexed citations
14.
Ikushima, Hiroaki, Tomoki Todo, Yasushi Ino, et al.. (2009). Autocrine TGF-β Signaling Maintains Tumorigenicity of Glioma-Initiating Cells through Sry-Related HMG-Box Factors. Cell stem cell. 5(5). 504–514. 438 indexed citations
15.
Fukuhara, Hiroshi, Yasushi Ino, Toshihiko Kuroda, Robert L. Martuza, & Tomoki Todo. (2005). Triple Gene-Deleted Oncolytic Herpes Simplex Virus Vector Double-Armed with Interleukin 18 and Soluble B7-1 Constructed by Bacterial Artificial Chromosome–Mediated System. Cancer Research. 65(23). 10663–10668. 76 indexed citations
16.
Fukuhara, Hiroshi, Robert L. Martuza, Samuel D. Rabkin, Yoshikazu Ito, & Tomoki Todo. (2005). Oncolytic Herpes Simplex Virus Vector G47Δ in Combination with Androgen Ablation for the Treatment of Human Prostate Adenocarcinoma. Clinical Cancer Research. 11(21). 7886–7890. 56 indexed citations
17.
Todo, Tomoki. (2002). Oncolytic Virus Therapy Using Genetically Engineered Herpes Simplex Viruses. Human Cell. 15(3). 151–159. 12 indexed citations
18.
19.
Todo, Tomoki, Tatsuya Kondo, Satoshi Nakamura, et al.. (1998). Neuronal localization of fibroblast growth factor-9 immunoreactivity in human and rat brain. Brain Research. 783(2). 179–187. 39 indexed citations
20.
Todo, Tomoki, et al.. (1991). Sudden appearance of a mycotic aneurysm of the intracavernous carotid artery after symptoms resembling cluster headache. Neurosurgery. 29(4). 594–594. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by James M. Markert Breakdown of academic impact, for papers by Samuel D. Rabkin Breakdown of academic impact, for papers by Cheryl A. Palmer Breakdown of academic impact, for papers by Ulrike Blömer Breakdown of academic impact, for papers by Robert L. Martuza Breakdown of academic impact, for papers by David A. Largaespada Breakdown of academic impact, for papers by Romain Zufferey Breakdown of academic impact, for papers by Ya‐Wen Chiang Breakdown of academic impact, for papers by Federico Mingozzi Breakdown of academic impact, for papers by Nicholas C. Dracopoli
Rankless by CCL
2026